ArticleFrontiers in immunology2025
Aberrant glycosylation patterns as potential biomarkers for diagnosis and disease progression in bullous pemphigoid.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Thematic Evolution and Diversification of Bullous Pemphigoid Research: A Bibliometric Analysis, 1959-2025.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Bullous pemphigoid (BP) is a prototypical autoimmune disease characterized by the production of autoantibodies against hemidesmosomal proteins BP180 and BP230. Aberrant glycosylation has emerged as a possible mechanism linked to the pathogenesis and progression of autoimmune diseases. However, the precise alterations in glycosylation in BP remain largely unknown. In this study, we explored the molecular mechanisms of abnormal glycosylation in BP pathogenesis. Methods: We systematically investigated the glycosylation changes in serum, blister fluid, and saliva from BP patients using lectin microarray assays and lectin-based enzyme-linked immunosorbent assays. Results: Our findings revealed increased glycosylation modifications of sialic acid, galactose, and fucose in serum proteins from BP patients, as well as enhanced fucosylation, galactosylation, and biantennary N-glycan glycosylation in blister fluid proteins. Notably, these abnormal modifications of monosaccharides correlated with the clinical indicators of BP. Furthermore, we observed that glycosylation patterns in saliva were associated with disease severity, suggesting their potential as valuable non-invasive diagnostic markers for BP. Conclusion: These discoveries indicate that aberrant glycosylation patterns may provide insights into the pathogenesis of BP and serve as potential biomarkers for diagnosing and monitoring the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.